Sale disclosed
Derrell Porter
Director
Common Stock
- Reported value
- $15.15K
- Reported price
- $2.345 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Acumen Pharmaceuticals, Inc.
Last 30 daysNo qualifying insider buying. No qualifying insider sales.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockSale | 6,460$2.35 / share | $15.15K | Jun 15Filed Jun 17 · 2d later | SEC filing |
| Director | Common StockSale | 12,800$2.33 / share | $29.77K | Jun 16Filed Jun 17 · 1d later | SEC filing |
| Director | Common StockSale | 13,040$2.33 / share | $30.32K | Jun 17Filed Jun 17 · 0d later | SEC filing |
| Director | Common StockSale | 6,400$2.23 / share | $14.27K | Jun 9Filed Jun 10 · 1d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.